메뉴 건너뛰기




Volumn 39, Issue 1, 2011, Pages 98-105

In vitro cytochrome P450-mediated metabolism of exemestane

Author keywords

[No Author keywords available]

Indexed keywords

17 HYDROEXEMESTANE; 6 HYDROXYMETHYLEXEMESTANE; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; CYTOCHROME P450 4A11; DRUG METABOLITE; EXEMESTANE; KETOCONAZOLE; RECOMBINANT ENZYME; TROLEANDOMYCIN; UNCLASSIFIED DRUG;

EID: 78650725834     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.032276     Document Type: Article
Times cited : (64)

References (33)
  • 1
    • 0343337185 scopus 로고    scopus 로고
    • Mechanism of induction of cytochrome P450 enzymes by the proestrogenic endocrine disruptor pesticide-methoxychlor: Interactions of methoxychlor metabolites with the constitutive androstane receptor system
    • Blizard D, Sueyoshi T, Negishi M, Dehal SS, and Kupfer D (2001) Mechanism of induction of cytochrome P450 enzymes by the proestrogenic endocrine disruptor pesticide-methoxychlor: interactions of methoxychlor metabolites with the constitutive androstane receptor system. Drug Metab Dispos 29:781-785.
    • (2001) Drug Metab Dispos , vol.29 , pp. 781-785
    • Blizard, D.1    Sueyoshi, T.2    Negishi, M.3    Dehal, S.S.4    Kupfer, D.5
  • 2
    • 0030430033 scopus 로고    scopus 로고
    • Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes
    • Bourrié M, Meunier V, Berger Y, and Fabre G (1996) Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 277:321-332.
    • (1996) J Pharmacol Exp Ther , vol.277 , pp. 321-332
    • Bourrié, M.1    Meunier, V.2    Berger, Y.3    Fabre, G.4
  • 3
    • 0027504510 scopus 로고
    • Synthesis and aromatase inhibition by potential metabolites of exemestane (6-methylenandrosta-1,4-diene-3,17-dione)
    • Buzzetti F, Di Salle E, Longo A, and Briatico G (1993) Synthesis and aromatase inhibition by potential metabolites of exemestane (6-methylenandrosta- 1,4-diene-3,17-dione). Steroids 58: 527-532.
    • (1993) Steroids , vol.58 , pp. 527-532
    • Buzzetti, F.1    Di Salle, E.2    Longo, A.3    Briatico, G.4
  • 4
    • 0038128342 scopus 로고    scopus 로고
    • Constitutive androstane receptor and pregnane X receptor gene expression in human liver: Interindividual variability and correlation with CYP2B6 mRNA levels
    • Chang TK, Bandiera SM, and Chen J (2003) Constitutive androstane receptor and pregnane X receptor gene expression in human liver: interindividual variability and correlation with CYP2B6 mRNA levels. Drug Metab Dispos 31:7-10.
    • (2003) Drug Metab Dispos , vol.31 , pp. 7-10
    • Chang, T.K.1    Bandiera, S.M.2    Chen, J.3
  • 5
    • 0034049569 scopus 로고    scopus 로고
    • Exemestane: A review of its use in postmenopausal women with advanced breast cancer
    • Clemett D and Lamb HM (2000) Exemestane: a review of its use in postmenopausal women with advanced breast cancer. Drugs 59:1279-1296.
    • (2000) Drugs , vol.59 , pp. 1279-1296
    • Clemett, D.1    Lamb, H.M.2
  • 8
    • 67649158224 scopus 로고    scopus 로고
    • A liquid chromatography-tandem mass spectrometry method for the simultaneous determination of exemestane and its metabolite 17-dihydroexemestane in human plasma
    • Corona G, Elia C, Casetta B, Diana C, Rosalen S, Bari M, and Toffoli G (2009) A liquid chromatography-tandem mass spectrometry method for the simultaneous determination of exemestane and its metabolite 17-dihydroexemestane in human plasma. J Mass Spectrom 44:920-928.
    • (2009) J Mass Spectrom , vol.44 , pp. 920-928
    • Corona, G.1    Elia, C.2    Casetta, B.3    Diana, C.4    Rosalen, S.5    Bari, M.6    Toffoli, G.7
  • 12
    • 43149086393 scopus 로고    scopus 로고
    • Chemoprevention of breast cancer
    • Cuzick J (2008) Chemoprevention of breast cancer. Breast Cancer 15:10-16.
    • (2008) Breast Cancer , vol.15 , pp. 10-16
    • Cuzick, J.1
  • 15
    • 0035150854 scopus 로고    scopus 로고
    • Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: Potential drug interactions with bupropion
    • Hesse LM, von Moltke LL, Shader RI, and Greenblatt DJ (2001) Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. Drug Metab Dispos 29:100-102.
    • (2001) Drug Metab Dispos , vol.29 , pp. 100-102
    • Hesse, L.M.1    Von Moltke, L.L.2    Shader, R.I.3    Greenblatt, D.J.4
  • 16
    • 2542446523 scopus 로고    scopus 로고
    • The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women
    • Jannuzzo MG, Poggesi I, Spinelli R, Rocchetti M, Cicioni P, and Buchan P (2004) The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women. Cancer Chemother Pharmacol 53:475-481.
    • (2004) Cancer Chemother Pharmacol , vol.53 , pp. 475-481
    • Jannuzzo, M.G.1    Poggesi, I.2    Spinelli, R.3    Rocchetti, M.4    Cicioni, P.5    Buchan, P.6
  • 20
    • 0346101833 scopus 로고    scopus 로고
    • Pharmacokinetics and dose finding of a potent aromatase inhibitor, aromasin (exemestane), in young males
    • Mauras N, Lima J, Patel D, Rini A, di Salle E, Kwok A, and Lippe B (2003) Pharmacokinetics and dose finding of a potent aromatase inhibitor, aromasin (exemestane), in young males. J Clin Endocrinol Metab 88:5951-5956.
    • (2003) J Clin Endocrinol Metab , vol.88 , pp. 5951-5956
    • Mauras, N.1    Lima, J.2    Patel, D.3    Rini, A.4    Di Salle, E.5    Kwok, A.6    Lippe, B.7
  • 21
    • 0028204887 scopus 로고
    • The molecular basis of genetic polymorphisms of drug metabolism
    • Meyer UA (1994) The molecular basis of genetic polymorphisms of drug metabolism. J Pharm Pharmacol 46 (Suppl 1):409-415.
    • (1994) J Pharm Pharmacol , vol.46 , Issue.SUPPL 1 , pp. 409-415
    • Meyer, U.A.1
  • 23
    • 85013917085 scopus 로고    scopus 로고
    • Genetic polymorphism of human cytochrome p450 involved in drug metabolism
    • Nagata K and Yamazoe Y (2002) Genetic polymorphism of human cytochrome p450 involved in drug metabolism. Drug Metab Pharmacokinet 17:167-189.
    • (2002) Drug Metab Pharmacokinet , vol.17 , pp. 167-189
    • Nagata, K.1    Yamazoe, Y.2
  • 24
    • 0031748287 scopus 로고    scopus 로고
    • Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones
    • Niwa T, Yabusaki Y, Honma K, Matsuo N, Tatsuta K, Ishibashi F, and Katagiri M (1998) Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica 28:539-547.
    • (1998) Xenobiotica , vol.28 , pp. 539-547
    • Niwa, T.1    Yabusaki, Y.2    Honma, K.3    Matsuo, N.4    Tatsuta, K.5    Ishibashi, F.6    Katagiri, M.7
  • 25
    • 0342980835 scopus 로고    scopus 로고
    • Novel metabolic pathway of estrone and 17betaestradiol catalyzed by cytochrome P-450
    • Ohe T, Hirobe M, and Mashino T (2000) Novel metabolic pathway of estrone and 17betaestradiol catalyzed by cytochrome P-450. Drug Metab Dispos 28:110-112.
    • (2000) Drug Metab Dispos , vol.28 , pp. 110-112
    • Ohe, T.1    Hirobe, M.2    Mashino, T.3
  • 27
    • 1642397469 scopus 로고    scopus 로고
    • Pilot study evaluating the pharmacokinetics, pharmacodynamics, and safety of the combination of exemestane and tamoxifen
    • Rivera E, Valero V, Francis D, Asnis AG, Schaaf LJ, Duncan B, and Hortobagyi GN (2004) Pilot study evaluating the pharmacokinetics, pharmacodynamics, and safety of the combination of exemestane and tamoxifen. Clin Cancer Res 10:1943-1948.
    • (2004) Clin Cancer Res , vol.10 , pp. 1943-1948
    • Rivera, E.1    Valero, V.2    Francis, D.3    Asnis, A.G.4    Schaaf, L.J.5    Duncan, B.6    Hortobagyi, G.N.7
  • 28
    • 77949468258 scopus 로고    scopus 로고
    • A review of the use of exemestane in early breast cancer
    • Robinson A (2009) A review of the use of exemestane in early breast cancer. Ther Clin Risk Manag 5:91-98.
    • (2009) Ther Clin Risk Manag , vol.5 , pp. 91-98
    • Robinson, A.1
  • 29
    • 0033811484 scopus 로고    scopus 로고
    • Allelic variants of human cytochrome P450 1A1 (CYP1A1): Effect of T461N and I462V substitutions on steroid hydroxylase specificity
    • Schwarz D, Kisselev P, Schunck WH, Chernogolov A, Boidol W, Cascorbi I, and Roots I (2000) Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. Pharmacogenetics 10:519-530.
    • (2000) Pharmacogenetics , vol.10 , pp. 519-530
    • Schwarz, D.1    Kisselev, P.2    Schunck, W.H.3    Chernogolov, A.4    Boidol, W.5    Cascorbi, I.6    Roots, I.7
  • 30
    • 0032414615 scopus 로고    scopus 로고
    • Molecular genetics of the human cytochrome P450 monooxygenase superfamily
    • Smith G, Stubbins MJ, Harries LW, and Wolf CR (1998) Molecular genetics of the human cytochrome P450 monooxygenase superfamily. Xenobiotica 28:1129-1165.
    • (1998) Xenobiotica , vol.28 , pp. 1129-1165
    • Smith, G.1    Stubbins, M.J.2    Harries, L.W.3    Wolf, C.R.4
  • 31
    • 0038002981 scopus 로고    scopus 로고
    • The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: Implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity
    • Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, and Desta Z (2003) The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 306:287-300.
    • (2003) J Pharmacol Exp Ther , vol.306 , pp. 287-300
    • Ward, B.A.1    Gorski, J.C.2    Jones, D.R.3    Hall, S.D.4    Flockhart, D.A.5    Desta, Z.6
  • 32
    • 19444376971 scopus 로고    scopus 로고
    • Drug metabolism and variability among patients in drug response
    • Wilkinson GR (2005) Drug metabolism and variability among patients in drug response. N Engl J Med 352:2211-2221.
    • (2005) N Engl J Med , vol.352 , pp. 2211-2221
    • Wilkinson, G.R.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.